RxDoctor Payments Data

Erin Vita

Nurse Practitioner · Pittsburgh, PANPI 1003165598

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 82 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$274
  • GSK$212
  • Novo Nordisk$192
  • Amgen$158
  • Amarin Pharma, Inc.$81
  • Abbott$63
  • plus $363 from 12 others

What the payments were for

  • Food & beverage$1,342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,342 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,559
Medicare patients
36
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$44,863
JardianceEmpagliflozin25$25,167
MounjaroTirzepatide19$19,422
EliquisApixaban23$18,243
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,760
RybelsusSemaglutide13$14,845
Breo ElliptaFluticasone/Vilanterol19$11,978
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,574
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$4,762
Gabapentin71$2,200
Ezetimibe43$1,743
Valsartan62$1,688
Albuterol Sulfate HfaAlbuterol Sulfate72$1,508
Atorvastatin Calcium170$1,504
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$192$59,70845 claims
GSKTrelegy Ellipta, Breo Ellipta$212$29,73847 claims
Lilly USA, LLCMounjaro$32$19,42219 claims
PfizerEliquis$19$18,24323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →